Tamaz Shaburishvili

Author PubWeight™ 13.60^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Spironolactone for heart failure with preserved ejection fraction.	N Engl J Med	2014	7.48
2	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.	Lancet	2011	2.42
3	Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.	Am Heart J	2011	1.95
4	Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.	Circ Heart Fail	2012	1.62
5	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.	J Thromb Thrombolysis	2012	0.90